When should small intestinal bacterial overgrowth (SIBO) testing be performed?

When to Perform SIBO Testing

SIBO testing should be performed whenever possible rather than using empirical antibiotic treatment in patients with suspected bacterial overgrowth, particularly in those with chronic diarrhea, bloating, and other gastrointestinal symptoms occurring in the context of predisposing conditions. 1

Clinical Scenarios Requiring SIBO Testing

High-Priority Testing Situations

Cancer Treatment Patients:

• SIBO occurs very commonly during and after cancer treatment 1
• Testing is preferred over empirical treatment to avoid antibiotic resistance and help with antibiotic stewardship 1
• Multiple diagnoses often coincide in this population, making testing essential to establish the true cause of symptoms 1

Post-Surgical Patients:

• After Crohn's disease resection (prevalence ~30%) 2
• Particularly important when blind loops, dysmotility, diverticulae, or strictures are present 2
• After intestinal resection for any indication
• Following upper GI surgery with persistent steatorrhea 1

Inflammatory Bowel Disease:

• Patients with recurrent symptoms following resection who have no evidence of active inflammation 2
• When symptoms mimic Crohn's disease (bloating, diarrhea, nausea, vomiting, weight loss, malnutrition) 2

Specific Symptom Patterns Warranting Testing

Test for SIBO when patients present with:

• Chronic diarrhea with bloating and abdominal discomfort 3
• Malabsorption syndrome (steatorrhea, weight loss, nutritional deficiencies) 4
• IBS-like symptoms in the presence of predisposing disorders 4
• Upper GI symptoms (nausea, halitosis, foul-smelling eructation, epigastric fullness) not explained by endoscopy 5
• Persistent symptoms despite pancreatic enzyme replacement therapy (PERT) - this often indicates underlying SIBO 1

Predisposing Conditions That Lower Testing Threshold

Consider SIBO testing in patients with:

• Pancreatic exocrine insufficiency (PEI) - SIBO occurs in up to 92% of chronic pancreatitis patients with PEI 6
• Anatomical abnormalities (dilatation, diverticulosis, strictures) 7
• Prior small bowel surgery or pseudo-obstruction 7
• Immunosuppression during chemotherapy 1
• Small bowel dilatation 8
• Proton pump inhibitor use 8
• Concurrent diabetes in chronic pancreatitis patients 6

Testing Methodology

Preferred Testing Approach:

1. Breath Testing (First-Line):

   • Hydrogen combined with methane breath testing is more effective than hydrogen testing alone 1
   • Glucose breath test is preferred over lactulose 9
   • The lactulose breath test should be discarded from future use due to incorrect premises and over-diagnosis 9

2. Endoscopic Aspiration (When Breath Testing Unavailable or Equivocal):

   • Qualitative assessment of small bowel aspirate is easier to perform than quantitative culture 1
   • Obtain agreement with local microbiology services on processing and reporting before undertaking 1
   • Culture of unwashed mucosal biopsies or brush swabs are alternatives to jejunal aspirates 7, 8

When Empirical Treatment May Be Acceptable

Limited circumstances where empirical treatment without testing is reasonable:

• When testing is unavailable 1
• High pretest probability with anatomical abnormalities (e.g., blind loops, diverticulosis, prior surgery, pseudo-obstruction) 7
• However, even in these cases, the 2025 BSG guidance emphasizes testing over empirical treatment whenever possible 1

Common Pitfalls to Avoid

• Don't assume negative breath test excludes SIBO - sensitivity ranges from 20-93% depending on methodology 3
• Don't use lactulose breath testing - it has poor reproducibility and leads to over-diagnosis 9
• Don't test patients already on antibiotics - this will yield false negatives
• Don't ignore rapid transit - fast orocaecal transit can confound interpretation of early hydrogen peaks 7
• Don't forget methane measurement - 3-25% of individuals are non-hydrogen producers 7
• Don't attribute low fecal elastase solely to PEI - it may indicate SIBO, untreated celiac disease, or watery stool 1

Key Diagnostic Considerations

The most recent and highest quality guidance (2025 BSG) represents a shift from previous recommendations: testing is now preferred over empirical treatment to address antibiotic stewardship concerns and the reality that multiple diagnoses often coexist, particularly in cancer patients 1. This contrasts with older 2019 guidance that suggested empirical treatment when diagnosis was likely 2.

When SIBO testing is positive, it should prompt investigation for underlying causes and consideration of other coexisting conditions such as bile acid malabsorption, pancreatic exocrine insufficiency, and functional bowel disorders 2.